CStone Pharmaceuticals (CSPHF) Comparison with companies in other sectors?

CStone Pharmaceuticals has a share price of 1.46B. You can analyze CStone Pharmaceuticals (CSPHF) competitors across different market sectors through stock heatmaps.

What are CSPHF's NET and operating margins?

CStone Pharmaceuticals (CSPHF) operating margin is around -0.51, and net profit margin is approximately -0.18 as of the latest reports.

In what way does CSPHF's earnings per share (EPS) trend reflect its financial momentum?

CStone Pharmaceuticals (CSPHF) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for CStone Pharmaceuticals is -62.50, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for CStone Pharmaceuticals?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for CStone Pharmaceuticals like P/E which is -111.09, P/B which is 19.33, and PEG which is -0.34. Compare them with sector averages to evaluate if the stock is priced fairly.

CStone Pharmaceuticals

CSPHF•PNK

Healthcare

Biotechnology

$0.63

$0.00(0.00%)

Fundamental Analysis of CStone Pharmaceuticals (CSPHF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.01

P/E Ratio

-62.50

ROE

-0.14%

Net Margin

-0.18%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$910.88M

Shares OutstandingTotal number of shares issued

$1.46B

Book Value/ShareNet worth per share

$0.23

Revenue/ShareAnnual revenue per share

$0.23

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.01

Net MarginNet income as percentage of revenue

-17.81%

Operating MarginOperating income as percentage of revenue

-50.50%

ROEReturn on shareholders' equity

-14.42%

ROAReturn on total assets

-4.54%

ROCEReturn on capital employed

-25.22%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.20

Cash/ShareCash and equivalents per share

$0.43

FCF YieldFree cash flow as percentage of market cap

-4.77%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CSPHFFinancial Ratios Analysis details for CSPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CSPHFSector Benchmarking details for CSPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for CStone Pharmaceuticals Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of CStone Pharmaceuticals. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account CStone Pharmaceuticals's unique business strengths and challenges.

Key Financial Metrics for CStone Pharmaceuticals

For CStone Pharmaceuticals, essential financial indicators include EPS -0.01, PE -62.50, and ROE -0.14. These key ratios reveal insights into CStone Pharmaceuticals's profitability, valuation, and operational health. Understanding these metrics enables you to compare CStone Pharmaceuticals with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of CStone Pharmaceuticals

Metrics like Net Margin -17.81% and ROA -4.54% shed light on how well CStone Pharmaceuticals is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether CStone Pharmaceuticals can sustain its operations and continue growing in the future.

Valuation and Market Position of CStone Pharmaceuticals

Using ratios such as P/B Ratio 19.33 and PEG Ratio -0.34, investors can assess whether CStone Pharmaceuticals is appropriately valued based on its financials and growth potential. These figures, combined with CStone Pharmaceuticals's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for CStone Pharmaceuticals

Financial health indicators, such as Debt/Equity Ratio 0.98 and Cash Flow $-0.20, provide a snapshot of CStone Pharmaceuticals's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like CStone Pharmaceuticals, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for CStone Pharmaceuticals

Investing in CStone Pharmaceuticals based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at CStone Pharmaceuticals focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;